AU2001296033A1 - Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37 - Google Patents

Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37

Info

Publication number: AU2001296033A1
Authority: AU; Australia
Prior art keywords: novel; protein; coupled receptor; gtp; guanosine triphosphate
Prior art date: 2000-11-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001296033A

Other languages

English (en)

Inventor

Hiraku Itadani

Takaharu Maruyama

Takao Nakamura

Kenichi Tanaka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MSD KK

Original Assignee

Banyu Phamaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-17

Filing date

2001-10-30

Publication date

2002-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27345218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001296033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-30 Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd

2002-05-27 Publication of AU2001296033A1 publication Critical patent/AU2001296033A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Immunology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Neurology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU2001296033A 2000-11-17 2001-10-30 Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37 Abandoned AU2001296033A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
JP2000351741		2000-11-17
JP2000-351741		2000-11-17
JP2001-38619		2001-02-15
JP2001038619		2001-02-15
JP2001077000		2001-03-16
JP2001-77000		2001-03-16
PCT/JP2001/009512 WO2002040669A1 (fr)	2000-11-17	2001-10-30	Bg37, nouvelle proteine du recepteur couple aux proteines g de liaison de guanosine triphosphate (gtp)

Publications (1)

Publication Number	Publication Date
AU2001296033A1 true AU2001296033A1 (en)	2002-05-27

Family

ID=27345218

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001296033A Abandoned AU2001296033A1 (en)	2000-11-17	2001-10-30	Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37

Country Status (8)

Country	Link
US (3)	US7198914B2 (fr)
EP (1)	EP1347052B1 (fr)
JP (1)	JP4003069B2 (fr)
AT (1)	ATE466939T1 (fr)
AU (1)	AU2001296033A1 (fr)
CA (1)	CA2429214A1 (fr)
DE (1)	DE60142079D1 (fr)
WO (1)	WO2002040669A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7354726B2 (en) *	2001-04-12	2008-04-08	Takeda Pharmaceutical Company Limited	Screening method
GB0208407D0 (en) *	2001-10-01	2002-05-22	Aventis Pharma Inc	A novel G protein-coupled receptor, GAVE10
EP1458755A2 (fr) *	2001-12-17	2004-09-22	Novartis AG	Nouveaux recepteurs couples a la proteine g et leurs sequences d'adn
WO2004043468A1 (fr) *	2002-11-12	2004-05-27	Takeda Pharmaceutical Company Limited	Procede de criblage
AU2003298111A1 (en) *	2002-11-22	2004-06-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
EP1591120A4 (fr) *	2003-01-28	2009-06-10	Takeda Chemical Industries Ltd	Agonistes de recepteurs
TW200539867A (en) *	2004-04-13	2005-12-16	Arena Pharm Inc	Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
CA2592461A1 (fr) *	2004-12-27	2006-07-06	Banyu Pharmaceutical Co., Ltd.	Medicaments destines a des maladies accompagnant des modifications des acides biliaires totaux ou des troubles du metabolisme lipidique et procede de criblage desdits medicaments
WO2007050628A2 (fr)	2005-10-24	2007-05-03	Andrew Young	Dispositif de derivation biliaire/pancreatique et procede pour le traitement de maladies metaboliques et d'autres maladies
BRPI0908719A2 (pt) *	2008-03-31	2015-08-18	Univ Columbia	Metodos de diagnóstico, prevenção e tratamento de doenças de massa óssea
US20110136788A1 (en) *	2008-08-07	2011-06-09	Minoru Maruyama	Therapeutic agent for irritable bowel syndrome
US9339480B2 (en)	2008-11-26	2016-05-17	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of obesity and diabetes
CN102316889B (zh)	2008-11-26	2014-11-26	萨蒂奥根制药公司	组合物及使用方法
WO2011053977A1 (fr)	2009-11-02	2011-05-05	The Trustees Of Columbia University In The City Of New York	Composés et méthodes d'inhibition de la synthèse de sérotonine
US20110294767A1 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2012328453B2 (en)	2011-10-28	2017-05-04	Shire Human Genetic Therapies, Inc.	Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
ES2633766T3 (es)	2011-10-28	2017-09-25	Lumena Pharmaceuticals Llc	Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09268A (ja)	1994-08-11	1997-01-07	Takeda Chem Ind Ltd	新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
US5858716A (en) *	1997-05-30	1999-01-12	Smithkline Beecham Corporation	H2CAA71 polynucleotides
AU4682999A (en)	1998-06-16	2000-01-05	Human Genome Sciences, Inc.	94 human secreted proteins
JP2000189171A (ja)	1998-12-25	2000-07-11	Banyu Pharmaceut Co Ltd	新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
WO2000058462A1 (fr)	1999-03-25	2000-10-05	Banyu Pharmaceutical Co., Ltd.	Nouvelles proteines de recepteur couplees aux proteines de liaison a la guanosine triphosphate (gtp), bg3
JP3221607B2 (ja)	1999-06-08	2001-10-22	学校法人加計学園	置換フェニル化合物の合成方法
JP3451338B2 (ja)	1999-07-30	2003-09-29	株式会社シギヤ精機製作所	研削盤に於ける砥石径測定装置
JP2001077000A (ja)	1999-09-02	2001-03-23	Nikon Corp	パターンの分割方法及び半導体デバイスの製造方法
AU2398501A (en)	1999-12-20	2001-07-03	Banyu Pharmaceutical Co., Ltd.	Novel guanosine triphosphate-binding protein-coupled receptor protein, bg26
EP1273659A4 (fr)	2000-04-12	2004-04-21	Takeda Chemical Industries Ltd	Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
AU2001277963A1 (en) *	2000-07-21	2002-02-05	Millennium Pharmaceuticals, Inc.	65494, a human g-protein-coupled receptor family member and uses thereof
AU2001280785A1 (en)	2000-07-27	2002-02-13	Incyte Genomics, Inc.	G-protein coupled receptors
JP2002112793A (ja)	2000-08-04	2002-04-16	Japan Science & Technology Corp	新規ｇ蛋白質共役受容体
ATE394487T1 (de)	2001-02-20	2008-05-15	Bayer Healthcare Ag	Menschlicher g-protein gekoppelter rezeptor
US6783969B1 (en) *	2001-03-05	2004-08-31	Nuvelo, Inc.	Cathepsin V-like polypeptides
US7354726B2 (en) *	2001-04-12	2008-04-08	Takeda Pharmaceutical Company Limited	Screening method
JPWO2002088355A1 (ja)	2001-04-25	2004-08-19	藤沢薬品工業株式会社	新規なグアノシン三リン酸結合タンパク質共役型の受容体ｐｌａｃｅ６００２３１２およびその遺伝子、並びにそれらの製造および用途

2001
- 2001-10-30 US US10/432,101 patent/US7198914B2/en not_active Expired - Fee Related
- 2001-10-30 CA CA002429214A patent/CA2429214A1/fr not_active Abandoned
- 2001-10-30 JP JP2002543664A patent/JP4003069B2/ja not_active Expired - Fee Related
- 2001-10-30 AU AU2001296033A patent/AU2001296033A1/en not_active Abandoned
- 2001-10-30 AT AT01976875T patent/ATE466939T1/de not_active IP Right Cessation
- 2001-10-30 DE DE60142079T patent/DE60142079D1/de not_active Expired - Lifetime
- 2001-10-30 WO PCT/JP2001/009512 patent/WO2002040669A1/fr not_active Ceased
- 2001-10-30 EP EP01976875A patent/EP1347052B1/fr not_active Revoked
2007
- 2007-02-08 US US11/704,546 patent/US7723046B2/en not_active Expired - Fee Related
2010
- 2010-03-03 US US12/716,906 patent/US8076455B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7198914B2 (en)	2007-04-03
DE60142079D1 (de)	2010-06-17
EP1347052B1 (fr)	2010-05-05
US8076455B2 (en)	2011-12-13
US20040086898A1 (en)	2004-05-06
US20070141642A1 (en)	2007-06-21
ATE466939T1 (de)	2010-05-15
CA2429214A1 (fr)	2003-05-15
EP1347052A1 (fr)	2003-09-24
US20100184236A1 (en)	2010-07-22
JPWO2002040669A1 (ja)	2005-06-02
WO2002040669A1 (fr)	2002-05-23
JP4003069B2 (ja)	2007-11-07
EP1347052A4 (fr)	2006-07-19
US7723046B2 (en)	2010-05-25

Publication	Publication Date	Title
AU2001296033A1 (en)	2002-05-27	Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37
Keirsebilck et al.	1998	Molecular cloning of the human p120ctnCatenin gene (CTNND1): Expression of multiple alternatively spliced isoforms
CN1329511C (zh)	2007-08-01	非内源的被组成型活化的人g蛋白偶联的受体
Pawson et al.	1993	SH2 and SH3 domains
Gorn et al.	1995	Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction.
CN1966520B (zh)	2012-07-11	结合血小板生成素受体的肽和化合物
Liu et al.	1995	Identification of a receptor/G-protein contact site critical for signaling specificity and G-protein activation.
Hermanns et al.	2000	Non-redundant signal transduction of interleukin-6-type cytokines: the adapter protein Shc is specifically recruited to the oncostatin M receptor
Posern et al.	1998	Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G
Chang et al.	2003	Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif
BR9604993B1 (pt)	2009-05-05	dna mutante codificando uma proteìna ahas mutante de sìntese de ácido acetohidróxi e proteìnas ahas mutantes.
CN1420929A (zh)	2003-05-28	非内源性组成型活化的已知g蛋白偶联受体
DE69834027D1 (de)	2006-05-18	Tumor-nekrose-faktor rezeptor 5
Wolffe et al.	1990	The cDNA sequence of mouse Pgp-1 and homology to human CD44 cell surface antigen and proteoglycan core/link proteins.
WO1997024436A3 (fr)	1997-09-12	Polypeptides formant liganos vis-a-vis de la proteine receptrice liee a la proteine g-, leur fabrication et utilisation
WO2001036447A3 (fr)	2002-08-15	Entites fonctionnelles de recepteur hormonal et procedes d'utilisation
Peterson et al.	2002	Identification of structural features in the G-protein regulatory motif required for regulation of heterotrimeric G-proteins
EP1017786A1 (fr)	2000-07-12	I- (kappa) b- kinases
Haines et al.	2005	The NLRR gene family and mouse development: Modified differential display PCR identifies NLRR-1 as a gene expressed in early somitic myoblasts
EP1116727A4 (fr)	2002-01-02	Derive de peptide
CA2413435A1 (fr)	2001-12-27	Lignee cellulaire recombinee exprimant gpcrx11 en tant que recepteur fonctionnel valide par l'angiopeptine et utile dans le criblage d'agonistes et antagonistes
EP1279744A3 (fr)	2004-05-26	Identification et utilisation des molécules impliquées dans la douleur
AU1691099A (en)	1999-07-19	Novel guanosine triphosphate (gtp)-binding protein conjugate type receptor proteins
US6750322B2 (en)	2004-06-15	Guanosine triphosphate (GTP) binding protein-coupled receptor proteins
Fox et al.	1991	The primary structure of Plasmodium falciparum DNA polymerase δ is similar to drug sensitive δ-like viral DNA polymerases